Mizuho Securities analyst Steven Valiquette has maintained their bullish stance on COR stock, giving a Buy rating yesterday.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Steven Valiquette has given his Buy rating due to a combination of factors indicating Cencora’s strong financial performance and growth potential. A key reason for the positive outlook is Cencora’s upward revision of its fiscal year 2025 earnings per share (EPS) guidance, which has been increased for the second time in 2025. This adjustment follows impressive first-quarter results where the EPS surpassed both the consensus and the analyst’s own expectations.
Another factor contributing to the Buy rating is the notable growth in Cencora’s U.S. Healthcare Solutions segment, which experienced a 13.6% increase in revenues year-over-year, outpacing market estimates. The strength in specialty distribution to physicians and the demand for GLP-1 drugs are pivotal in driving this growth. Despite some challenges in the international segment, like a decline in reported EBIT, the company showed positive growth on a constant currency basis, bolstered by its European distribution business. These elements collectively underpin the decision to maintain a favorable rating and a price target of $280.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $288.00 price target.
COR’s price has also changed slightly for the past six months – from $241.250 to $253.280, which is a 4.99% increase.